Allergan PLC (AGN)

pos +7.17
Today's Range: 265.51 - 277.87 | AGN Avg Daily Volume: 3,105,600
Last Update: 10/08/15 - 4:02 PM EDT
Volume: 3,983,425
YTD Performance: 4.50%
Open: $268.67
Previous Close: $268.99
52 Week Range: $208.64 - $340.34
Oustanding Shares: 393,635,637
Market Cap: 107,415,292,625
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 12 13
Moderate Buy 3 3 3 2
Hold 0 0 0 1
Moderate Sell 1 1 1 0
Strong Sell 0 0 0 0
Mean Rec. 1.34 1.34 1.34 1.22
Latest Dividend: 0.05
Latest Dividend Yield: 0.08%
Dividend Ex-Date: 02/25/15
Price Earnings Ratio: -25.43
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
-25.43 0.00 24.86
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-12.38% 10.52% 0.00%
Revenue 50.50 1.85 0.41
Net Income 0.00 -7.29 0.00
EPS 0.00 -4.53 0.00
Earnings for AGN:
Revenue 13.06B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $4.34 $4.54 $17.79 $16.32
Number of Analysts 2 1 6 6
High Estimate $4.42 $4.54 $18.40 $17.02
Low Estimate $4.25 $4.54 $17.25 $15.55
Prior Year $3.19 $3.91 $13.98 $17.79
Growth Rate (Year over Year) 35.89% 16.11% 27.23% -8.27%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Before you sell them, ask yourself at what multiple you sell.
We lighten up on what we bought when we had courage.
There's blood in the water.
Sep 29, 2015 | 7:34 AM EDT
Shares of AGN now seen reaching $311, according to Leerink Partners. Estimates also reduced, given the company's new guidance. Outperfo...
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
Sadly, this selloff makes sense.
Some smaller biotechs offer good value at current levels.
This market has become one giant exercise in stupidity.
Management team and acquisitions help make pharma company a buy.

Columnist Conversations

There have been no reversal indications aka sell triggers in the SPX against the cycles I was watching. The b...
If you want to make a point about the current action in the FANG stocks you completely undermine any credibili...
Thanks for vote of confidence, but I'm not the market. I just wanted to point out...while you could be right ...
You are brilliant.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.